Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04726241 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT04726241 · ClinicalTrials.gov record · last posted 2026-08-25

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

StatusRecruiting
PhasePhase 1/2
Started2022-04-18
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
This study aims to use clinical and biological characteristics of acute leukemias to screen for patient eligibility for available pediatric leukemia sub-trials. Testing bone marrow and blood from patients with leukemia that has come back after treatment or is difficult to treat may provide information about the patient's leukemia that is important when deciding how to best treat it, and may help doctors find better ways to diagnose and treat leukemia in children, adolescents, and young adults.

Amendment record 38 amendments on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended 38 times since 2021-01-22; most recent amendment 2026-06-16. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

2022-04-28
Status change Not Yet Recruiting→Recruitingv2
Trial Details
NCT Number NCT04726241
Lead Sponsor PedAL BCU, LLC
Collaborators: Children's Oncology Group, National Cancer Institute (NCI)
Conditions Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Acute Myeloid Leukemia Post Cytotoxic Therapy, Juvenile Myelomonocytic Leukemia, Mixed Phenotype Acute Leukemia, Myelodysplastic Syndrome, Myelodysplastic Syndrome Post Cytotoxic Therapy, Myeloid Leukemia Associated With Down Syndrome
Enrollment 960 participants
Start Date 2022-04-18
Primary Completion 2030-12-31 (estimated)
Study Completion 2030-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-08-25